Table 1 Sociodemographic, clinical, and treatment response data from background population controls, as well as patients with MDD at baseline and week 8 follow-up.

From: Systemic DNA and RNA damage from oxidation after serotonergic treatment of unipolar depression

Variable

Controls, full (N = 856)

Controls, matched (N = 67)

Baseline (n = 100)

Week 8 (n = 82)

Sex (F (%) / M (%))

511 (59.7) / 345 (40.3)

50 (74.6) / 17 (25.4)

73 (73.0) / 27 (27.0)*

 

Age (years)

38.4 (4.6)

28.5 (2.4)

27.0 (8.1)*

 

Smokers (N (%))

131 (15%)

9 (13.4)

19 (19%)

 

BMI (kg/m2)

24.5 (4.7)

22.9 (4.4)

24.6 (5.6)#

 

Mean glucose (mmol/L)

5.8 (0.5)

5.7 (0.4)

5.6 (0.9)*

 

Plasma creatinine (µM)

74.1 (14.5)

74.8 (16.3)

71.8 (13.2)

 

Plasma escitalopram (nM) (n = 71)

   

78.3 (45.3)

Plasma duloxetine (nM) (n = 7)

   

139.6 (82.0)

HAM-D6

  

12.3 (1.6)

5.9 (3.8)**

HAM-D17

  

22.9 (3.4)

11.5 (6.6)**

Treatment response (N (%))

    

 Non-responders

   

14 (17.3)

 Intermediate responders

   

44 (54.3)

 Remitters

   

23 (28.4)

  1. Signifcant differences between the groups are marked with * (full control population) and # (fully age- and sex-matched control population) vs. patients at baseline, or ** (patients at baseline vs. week 8). Data were analyzed with independent samples t-tests, paired samples t-tests or chi-squared tests, as appropriate. Data are presented as means (standard deviation) if not otherwise stated.
Back to article page